المؤلفون: Azad, T, Janse van Rensburg, HJ, Lightbody, ED, Neveu, B, Champagne, A, Ghaffari, A, Kay, VR, Hao, Y, Shen, H, Yeung, B, Croy, BA, Guan, KL, Pouliot, F, Zhang, J, Nicol, CJB, Yang, X

المصدر: Nature communications. 9(1)

مصطلحات موضوعية: Animals, Humans, Protein-Serine-Threonine Kinases, Receptors, Vascular Endothelial Growth Factor, Adaptor Proteins, Signal Transducing, Tumor Suppressor Proteins, Phosphoproteins, Transcription Factors, Blotting, Western, Immunohistochemistry, Mutagenesis, Site-Directed, Biosensing Techniques, Signal Transduction, Female, Phosphatidylinositol 3-Kinases, HEK293 Cells, A549 Cells, Adaptor Proteins, Signal Transducing, Blotting, Western, Mutagenesis, Site-Directed, Receptors, Vascular Endothelial Growth Factor

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/4gc856dz

المؤلفون: Tahri S; Dana-Farber Cancer Institute, United States., Piccinelli S; Dana-Farber Cancer Institute, Boston, Massachusetts, Netherlands., Su NK; Harvard Medical School, United States., Lampe LM; Christian-Albrechts University, Germany., Dong H; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Vergara Cadavid J; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Boiarsky R; CSAIL, United States., Papazian N; Erasmus MC, Rotterdam, Netherlands., Lightbody ED; Harvard Medical School, United States., Cao A; Harvard Medical School, United States., Alberge JB; Harvard Medical School, United States., Ferrari de Andrade L; Icahn School of Medicine at Mount Sinai, New York, New York, United States., Rahmat M; Harvard Medical School, United States., Shen Y; Cancer Science Institute of Singapore, Singapore., Blanco Fernández L; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Zabaleta A; Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Guenther A; Christian-Albrechts University, Kiel, Germany., Getz G; Broad Institute, Mass General Hospital, Cambridge, Massachusetts, United States., Sonneveld P; Erasmus MC Cancer Institute Rotterdam, Rotterdam, Netherlands., Cupedo T; Erasmus University Medical Center, Rotterdam, Netherlands., Wucherpfennig KW; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Ghobrial IM; Harvard Medical School, United States., Romee R; Harvard Medical School, United States.

المصدر: Blood advances [Blood Adv] 2024 Aug 06. Date of Electronic Publication: 2024 Aug 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

المؤلفون: Nadeem O; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Aranha MP; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Redd R; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Timonian M; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Magidson S; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lightbody ED; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Alberge JB; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Bertamini L; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dutta AK; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., El-Khoury H; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bustoros M; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, New York, USA., Laubach JP; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bianchi G; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., O'Donnell E; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wu T; Broad Institute, Boston, MA, USA., Tsuji J; Broad Institute, Boston, MA, USA., Anderson K; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Broad Institute, Boston, MA, USA., Trippa L; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Richardson PG; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sklavenitis-Pistofidis R; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Ghobrial IM; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

المصدر: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Apr 19. Date of Electronic Publication: 2024 Apr 19.

نوع المنشور: Preprint

بيانات الدورية: Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE

المؤلفون: Sklavenitis-Pistofidis R; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece., Lightbody ED; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Reidy M; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tsuji J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Aranha MP; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Huynh D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chong SJF; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hackett L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haradhvala NJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Wu T; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Berrios B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Alberge JB; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dutta A; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Davids MS; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Papaioannou M; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Hematology Unit, 1st Internal Medicine Department, AHEPA University Hospital, Thessaloniki, Greece., Getz G; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Ghobrial IM; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000, France.; Department of Hematology, CHU Lille, Lille University, 59000, France.

المصدر: BioRxiv : the preprint server for biology [bioRxiv] 2023 Aug 03. Date of Electronic Publication: 2023 Aug 03.

نوع المنشور: Preprint

بيانات الدورية: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

المؤلفون: Shakfa N; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Li D; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Conseil G; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Lightbody ED; Dana-Farber Cancer Institute, Harvard University, Cambridge, Massachusetts, USA., Wilson-Sanchez J; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Hamade A; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Chenard S; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Jawa NA; Centre for Neuroscience Studies & School of Medicine, Queen's University, Kingston, Ontario, Canada., Laight BJ; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.; Pathology and Molecular Medicine, Queen's University Cancer Research Institute, Kingston, Ontario, Canada., Afriyie-Asante A; Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Tyryshkin K; Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada., Koebel M; Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada., Koti M; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada kotim@queensu.ca.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Apr; Vol. 11 (4).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology , Antineoplastic Agents*/therapeutic use, Humans ; Mice ; Female ; Animals ; PTEN Phosphohydrolase/genetics ; Ascites/genetics ; Genotype ; Interferons ; Tumor Microenvironment/genetics

المؤلفون: Dutta AK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Alberge JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Lightbody ED; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Boehner CJ; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Dunford A; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Mouhieddine TH; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Cowan AN; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Su NK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Horowitz EM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Barr H; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Hevenor L; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Beckwith JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Perry J; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Cao A; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Lin Z; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kuhr FK; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Mastro RGD; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Nadeem O; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Greipp PT; Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota., Stewart C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Auclair D; Multiple Myeloma Research Foundation, Norwalk, Connecticut., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

المصدر: Cancer discovery [Cancer Discov] 2023 Feb 06; Vol. 13 (2), pp. 348-363.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Neoplastic Cells, Circulating*/pathology , Multiple Myeloma*/genetics , Multiple Myeloma*/pathology, Humans ; Base Sequence ; Bone Marrow ; Whole Genome Sequencing

المؤلفون: Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aranha MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Redd RA; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Baginska J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haradhvala NJ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA 02138, USA., Hallisey M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dutta AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Savell A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Varmeh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Ujwary S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Zavidij O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aguet F; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Wu T; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Flechon L; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France., Anand S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Rosenblatt JM; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Zonder J; Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA., Vredenburgh JJ; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Boruchov A; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Bhutani M; Levine Cancer Institute, Charlotte, NC 28204, USA., Usmani SZ; Levine Cancer Institute, Charlotte, NC 28204, USA., Matous J; Colorado Blood Cancer Institute, Denver, CO 80218, USA., Yee AJ; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Jakubowiak A; University of Chicago Cancer Center, Chicago, IL 60637, USA., Laubach J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France; Department of Hematology, CHU Lille, Lille University, 59000 Lille, France., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Badros AZ; University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA., Mateos MV; University Hospital of Salamanca - Instituto de Investigación Biomédica de Salamanca, 37007 Salamanca, Spain., Trippa L; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Getz G; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: gadgetz@broadinstitute.org., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.

المصدر: Cancer cell [Cancer Cell] 2022 Nov 14; Vol. 40 (11), pp. 1358-1373.e8.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Smoldering Multiple Myeloma*/therapy, Humans ; Biomarkers ; Disease Progression ; Immunologic Factors ; Immunotherapy ; Lenalidomide/adverse effects ; Clinical Trials, Phase II as Topic

المؤلفون: El-Khoury H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lee DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Cea-Curry CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Barr H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Murphy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sakrikar D; The Binding Site, Rochester, MN, USA., Barnidge D; The Binding Site, Rochester, MN, USA., Bustoros M; Department of Medical Oncology, Weill Cornell Medicine, New York, NY, USA., Leblebjian H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA., Cowan A; Alix School of Medicine, The Mayo Clinic, Rochester, MN, USA., Davis MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Amstutz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Perkins MC; The Binding Site Group, Birmingham, UK., Harding S; The Binding Site Group, Birmingham, UK., Mo CC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Kapoor P; The Mayo Clinic, Rochester, MN, USA., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA; International Myeloma Foundation, North Hollywood, CA, USA., Borrello IM; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Fonseca R; Department of Medical Oncology, The Mayo Clinic, Phoenix, AZ, USA., Weiss ST; Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Karlson E; Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rebbeck TR; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Harvard Medical School, Boston, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.

المصدر: The Lancet. Haematology [Lancet Haematol] 2022 May; Vol. 9 (5), pp. e340-e349. Date of Electronic Publication: 2022 Mar 25.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Monoclonal Gammopathy of Undetermined Significance*/epidemiology , Multiple Myeloma*/epidemiology , Paraproteinemias*/diagnosis , Paraproteinemias*/epidemiology, Cohort Studies ; Female ; Humans ; Male ; Mass Spectrometry ; Prevalence

المؤلفون: Dutta AK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Alberge JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lightbody ED; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. irene_ghobrial@dfci.harvard.edu.

المصدر: Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2022 Apr; Vol. 19 (4), pp. 223-236. Date of Electronic Publication: 2022 Jan 11.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500077 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-4782 (Electronic) Linking ISSN: 17594774 NLM ISO Abbreviation: Nat Rev Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Monoclonal Gammopathy of Undetermined Significance*/genetics , Monoclonal Gammopathy of Undetermined Significance*/pathology , Multiple Myeloma*/genetics , Multiple Myeloma*/pathology , Multiple Myeloma*/therapy, Clonal Evolution/genetics ; Disease Progression ; Humans ; Precision Medicine ; Tumor Microenvironment

المؤلفون: Hallisey M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Dennis J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Abrecht C; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Pistofidis RS; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Schork AN; Longwood Medical Area CyTOF Core, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lightbody ED; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Heilpern-Mallory D; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Severgnini M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Ghobrial IM; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hodi FS; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Baginska J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

المصدر: STAR protocols [STAR Protoc] 2022 Feb 17; Vol. 3 (1), pp. 101163. Date of Electronic Publication: 2022 Feb 17 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101769501 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-1667 (Electronic) Linking ISSN: 26661667 NLM ISO Abbreviation: STAR Protoc Subsets: MEDLINE

مواضيع طبية MeSH: Bone Marrow* , Bone Marrow Cells*, Flow Cytometry/methods ; Humans ; Immunophenotyping ; Staining and Labeling